Umbilical cord blood graft engineering: Challenges and opportunities

P. A. Thompson; K. Rezvani; C. M. Hosing; B. Oran; A. L. Olson; U. R. Popat; A. M. Alousi; N. D. Shah; S. Parmar; C. Bollard; P. Hanley; P. Kebriaei; L. Cooper; J. Kellner; I. K. McNiece; E. J. Shpall

doi:10.1038/bmt.2015.97

Umbilical cord blood graft engineering: Challenges and opportunities

P. A. Thompson, K. Rezvani, C. M. Hosing, B. Oran, A. L. Olson, U. R. Popat, A. M. Alousi, N. D. Shah, S. Parmar, C. Bollard, P. Hanley, P. Kebriaei, L. Cooper, J. Kellner, I. K. McNiece, E. J. Shpall

Research output: Contribution to journal › Article › peer-review

23 Scopus citations

Abstract

We are entering a very exciting era in umbilical cord blood transplantation (UCBT), where many of the associated formidable challenges may become treatable by ex vivo graft manipulation and/or adoptive immunotherapy utilizing specific cellular products. We envisage the use of double UCBT rather than single UCBT for most patients; this allows for greater ability to treat larger patients as well as to manipulate the graft. Ex vivo expansion and/or fucosylation of one cord will achieve more rapid engraftment, minimize the period of neutropenia and also give certainty that the other cord will provide long-term engraftment/immune reconstitution. The non-expanded (and future dominant) cord could be chosen for characteristics such as better HLA matching to minimize GvHD, or larger cell counts to enable part of the unit to be utilized for the development of specific cellular therapies such as the production of virus-specificT-cells or chimeric-antigen receptor T-cells which are reviewed in this study.

Original language	English (US)
Pages (from-to)	S55-S62
Journal	Bone marrow transplantation
Volume	50
DOIs	https://doi.org/10.1038/bmt.2015.97
State	Published - Jun 6 2015

ASJC Scopus subject areas

Hematology
Transplantation

Access to Document

10.1038/bmt.2015.97

Cite this

Thompson, P. A., Rezvani, K., Hosing, C. M., Oran, B., Olson, A. L., Popat, U. R., Alousi, A. M., Shah, N. D., Parmar, S., Bollard, C., Hanley, P., Kebriaei, P., Cooper, L., Kellner, J., McNiece, I. K., & Shpall, E. J. (2015). Umbilical cord blood graft engineering: Challenges and opportunities. Bone marrow transplantation, 50, S55-S62. https://doi.org/10.1038/bmt.2015.97

@article{dc514b5c247c4a328c5c2ade32aec93f,

title = "Umbilical cord blood graft engineering: Challenges and opportunities",

abstract = "We are entering a very exciting era in umbilical cord blood transplantation (UCBT), where many of the associated formidable challenges may become treatable by ex vivo graft manipulation and/or adoptive immunotherapy utilizing specific cellular products. We envisage the use of double UCBT rather than single UCBT for most patients; this allows for greater ability to treat larger patients as well as to manipulate the graft. Ex vivo expansion and/or fucosylation of one cord will achieve more rapid engraftment, minimize the period of neutropenia and also give certainty that the other cord will provide long-term engraftment/immune reconstitution. The non-expanded (and future dominant) cord could be chosen for characteristics such as better HLA matching to minimize GvHD, or larger cell counts to enable part of the unit to be utilized for the development of specific cellular therapies such as the production of virus-specificT-cells or chimeric-antigen receptor T-cells which are reviewed in this study.",

author = "Thompson, {P. A.} and K. Rezvani and Hosing, {C. M.} and B. Oran and Olson, {A. L.} and Popat, {U. R.} and Alousi, {A. M.} and Shah, {N. D.} and S. Parmar and C. Bollard and P. Hanley and P. Kebriaei and L. Cooper and J. Kellner and McNiece, {I. K.} and Shpall, {E. J.}",

year = "2015",

month = jun,

day = "6",

doi = "10.1038/bmt.2015.97",

language = "English (US)",

volume = "50",

pages = "S55--S62",

journal = "Bone marrow transplantation",

issn = "0268-3369",

publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Umbilical cord blood graft engineering

T2 - Challenges and opportunities

AU - Thompson, P. A.

AU - Rezvani, K.

AU - Hosing, C. M.

AU - Oran, B.

AU - Olson, A. L.

AU - Popat, U. R.

AU - Alousi, A. M.

AU - Shah, N. D.

AU - Parmar, S.

AU - Bollard, C.

AU - Hanley, P.

AU - Kebriaei, P.

AU - Cooper, L.

AU - Kellner, J.

AU - McNiece, I. K.

AU - Shpall, E. J.

PY - 2015/6/6

Y1 - 2015/6/6

N2 - We are entering a very exciting era in umbilical cord blood transplantation (UCBT), where many of the associated formidable challenges may become treatable by ex vivo graft manipulation and/or adoptive immunotherapy utilizing specific cellular products. We envisage the use of double UCBT rather than single UCBT for most patients; this allows for greater ability to treat larger patients as well as to manipulate the graft. Ex vivo expansion and/or fucosylation of one cord will achieve more rapid engraftment, minimize the period of neutropenia and also give certainty that the other cord will provide long-term engraftment/immune reconstitution. The non-expanded (and future dominant) cord could be chosen for characteristics such as better HLA matching to minimize GvHD, or larger cell counts to enable part of the unit to be utilized for the development of specific cellular therapies such as the production of virus-specificT-cells or chimeric-antigen receptor T-cells which are reviewed in this study.

AB - We are entering a very exciting era in umbilical cord blood transplantation (UCBT), where many of the associated formidable challenges may become treatable by ex vivo graft manipulation and/or adoptive immunotherapy utilizing specific cellular products. We envisage the use of double UCBT rather than single UCBT for most patients; this allows for greater ability to treat larger patients as well as to manipulate the graft. Ex vivo expansion and/or fucosylation of one cord will achieve more rapid engraftment, minimize the period of neutropenia and also give certainty that the other cord will provide long-term engraftment/immune reconstitution. The non-expanded (and future dominant) cord could be chosen for characteristics such as better HLA matching to minimize GvHD, or larger cell counts to enable part of the unit to be utilized for the development of specific cellular therapies such as the production of virus-specificT-cells or chimeric-antigen receptor T-cells which are reviewed in this study.

UR - http://www.scopus.com/inward/record.url?scp=84930450382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930450382&partnerID=8YFLogxK

U2 - 10.1038/bmt.2015.97

DO - 10.1038/bmt.2015.97

M3 - Article

C2 - 26039209

AN - SCOPUS:84930450382

SN - 0268-3369

VL - 50

SP - S55-S62

JO - Bone marrow transplantation

JF - Bone marrow transplantation

ER -

Umbilical cord blood graft engineering: Challenges and opportunities

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this